Donanemab: What is the new Alzheimer’s drug rejected by the NHS?
Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
pharmaphorum14h
UK launches scheme to boost dementia trial participation
The Dementia Trials Accelerator (DTA) – which will be spearheaded by the UK Dementia Research Institute (UK DRI) and Health ...
MedPage Today22h
Med Student Killed; Puberty Blocker Data Go Unpublished; Alzheimer's Trial Inquiry
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...
Outsourcing-pharma1d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...
openaccessgovernment1d
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...